Meeting
2020 Gastrointestinal Cancers Symposium
Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup.
Authors
Masatoshi Kudo
Kindai University, Osaka, Japan
Masatoshi Kudo , Ho Yeong Lim , Ann-Lii Cheng , Yee Chao , Thomas Yau , Sadahisa Ogasawara , Masayuki Kurosaki , Naoki Morimoto , Kazuyoshi Ohkawa , Tatsuya Yamashita , Kyung-Hun Lee , Erluo Chen , Abby B. Siegel , Baek-Yeol Ryoo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02702401
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 526)
Abstract #
526
Poster Bd #
C7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
First Author: Shukui Qin
Poster
2022 ASCO Annual Meeting
Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
First Author: Shukui Qin
Poster
2021 ASCO Annual Meeting
Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.
First Author: Richard S. Finn
Poster
2017 ASCO Annual Meeting
Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.
First Author: Richard S. Finn